Current and new frontiers in hereditary cancer surveillance: Opportunities for liquid biopsy.
Kirsten M Farncombe, Derek Wong, Maia L Norman...
https://pubmed.ncbi.nlm.nih.gov/37802042/Actively Recruiting
Led by University Health Network, Toronto · Updated on 2026-10-08
1000
Participants Needed
8
Research Sites
104 weeks
Total Duration
Researchers are evaluating an experimental blood test called cell-free DNA cfDNA analysis to detect early tumors in patients with hereditary cancer syndromes. This study aims to compare the cancer detection rates between patients receiving this new blood test and those receiving standard cancer care. It also seeks to determine if the test leads to earlier cancer diagnosis and how it impacts patient outcomes, including quality of life and psychological distress. Participants are divided into two groups. Those in the experimental group provide blood samples every four months for four years, which are analyzed for cfDNA to detect cancer-related genetic changes. Results are shared with participants, and if positive, follow-up diagnostic tests are offered. The control group continues standard cancer surveillance without the cfDNA test. Both groups complete questionnaires and interviews about their experiences and perceptions of the testing. Throughout the study, participants undergo regular blood sample collections alongside routine clinical care when possible to minimize extra procedures. Researchers assess cancer detection rates, the timing of cancer diagnosis, and psychological effects such as cancer worry and anxiety over four years. The study also monitors how access to cfDNA results influences patients perceptions and quality of life. This study is expected to last until 2031, with primary outcomes assessed over four years from enrollment.
CONDITIONS
CfDNA in Hereditary And High-risk Malignancies 2
J
Julia Sobotka, MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Health Network, Toronto
Lead Sponsor
British Columbia Cancer Agency
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - 4 years
Participants in the experimental group provide blood samples every 4 months for 4 years for cell-free DNA analysis. Control group participants continue with standard cancer surveillance. All participants complete questionnaires and interviews about their experiences.
Blood samples every 4 months; questionnaire and interview sessions periodically
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kirsten M Farncombe, Derek Wong, Maia L Norman...
https://pubmed.ncbi.nlm.nih.gov/37802042/University Health Network, Toronto
Lead Sponsor
British Columbia Cancer Agency
Collaborating Sponsor